Treatment of leiomyomata with intranasal or subcutaneous leuprolide, a gonadotropin-releasing hormone agonist.

Friedman AJ, Barbieri RL, Benacerraf BR, Schiff I

Fertility and sterility1 Oct 1987Cited by 80 (Europe PMC)

PMID3115833DOI10.1016/s0015-0282(16)59464-3PepBankPUB-03115833

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In women with leiomyomata, subcutaneous leuprolide significantly reduced uterine volume from 368 to 202 cm3 at 12 weeks.
In plain wordsIn women with fibroids, subcutaneous leuprolide reduced uterine volume from 368 to 202 cm3 at 12 weeks.
Peptide
Leuprolide
Outcome
DecreaseUterine volume at 12 weeks
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Uterine Volume · Reproductive and sexual health
Studied dose
500 micrograms/day · subcutaneous · 12 weeksAs given in this study (human).
Measurements
Uterine volume
368 cm3
pretreatment
Uterine volume
202 cm3
12 weeks
Source sentences
Summary
In the SC group, a significant reduction in uterine volume occurred from a pretreatment volume of 368 +/- 60 (mean +/- standard error of the mean [SEM]) cm3 to 202 +/- 61 cm3 at 12 weeks of therapy (P less than 0.01) and to 172 +/- 49 cm3 at 24 weeks of therapy (P less than 0.005).
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen premenopausal women with uterine leiomyomata were randomized to receive a gonadotropin-releasing hormone agonist (GnRH-a), leuprolide, either by daily subcutaneous (SC) injection (500 micrograms/day) or by intranasal (IN) spray (1600 micrograms/day) for 24 weeks.
Report a problemFND-0311583301
02HumanNon-randomized trialEfficacy outcome
In women with leiomyomata, subcutaneous leuprolide significantly reduced uterine volume from 368 to 172 cm3 at 24 weeks.
In plain wordsIn women with fibroids, subcutaneous leuprolide reduced uterine volume from 368 to 172 cm3 at 24 weeks.
Peptide
Leuprolide
Outcome
DecreaseUterine volume at 24 weeks
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Uterine Volume · Reproductive and sexual health
Studied dose
500 micrograms/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Uterine volume
368 cm3
pretreatment
Uterine volume
172 cm3
24 weeks
Source sentences
Summary
In the SC group, a significant reduction in uterine volume occurred from a pretreatment volume of 368 +/- 60 (mean +/- standard error of the mean [SEM]) cm3 to 202 +/- 61 cm3 at 12 weeks of therapy (P less than 0.01) and to 172 +/- 49 cm3 at 24 weeks of therapy (P less than 0.005).
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen premenopausal women with uterine leiomyomata were randomized to receive a gonadotropin-releasing hormone agonist (GnRH-a), leuprolide, either by daily subcutaneous (SC) injection (500 micrograms/day) or by intranasal (IN) spray (1600 micrograms/day) for 24 weeks.
Report a problemFND-0311583302
03HumanNon-randomized trialEfficacy outcome
In women with leiomyomata, intranasal leuprolide did not significantly reduce uterine volume.
In plain wordsIn women with fibroids, intranasal leuprolide did not significantly reduce uterine volume.
Peptide
Leuprolide
Outcome
No significant changeIntranasal uterine volume response
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Uterine Volume · Reproductive and sexual health
Studied dose
1600 micrograms/day · intranasal · 24 weeksAs given in this study (human).
Source sentences
Summary
In the IN group, no significant reduction in uterine volume occurred.
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen premenopausal women with uterine leiomyomata were randomized to receive a gonadotropin-releasing hormone agonist (GnRH-a), leuprolide, either by daily subcutaneous (SC) injection (500 micrograms/day) or by intranasal (IN) spray (1600 micrograms/day) for 24 weeks.
Report a problemFND-0311583303
04HumanNon-randomized trialEfficacy outcome
In women with leiomyomata, uterine volume increased to 296 cm3 four months after subcutaneous leuprolide ended.
In plain wordsIn women with fibroids, uterine volume increased to 296 cm3 four months after subcutaneous leuprolide ended.
Peptide
Leuprolide
Outcome
IncreaseUterine volume after treatment
Study
n: not reported in source
Comparator
End of therapy
Outcome group
Uterine Volume · Reproductive and sexual health
Studied dose
500 micrograms/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Uterine volume
296 cm3
four months after therapy
Source sentences
Summary
Four months after completing therapy, uterine volume increased to 296 +/- 104 cm3 in the SC group, which was not significantly different from pretreatment volume.
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen premenopausal women with uterine leiomyomata were randomized to receive a gonadotropin-releasing hormone agonist (GnRH-a), leuprolide, either by daily subcutaneous (SC) injection (500 micrograms/day) or by intranasal (IN) spray (1600 micrograms/day) for 24 weeks.
Report a problemFND-0311583305
05HumanNon-randomized trialEfficacy outcome
In women with leiomyomata, uterine volume four months after subcutaneous leuprolide did not differ significantly from pretreatment.
In plain wordsIn women with fibroids, uterine volume four months after subcutaneous leuprolide did not differ significantly from pretreatment.
Peptide
Leuprolide
Outcome
No significant changePost-treatment uterine volume versus pretreatment
Study
n: not reported in source
Comparator
Pretreatment
Outcome group
Uterine Volume · Reproductive and sexual health
Studied dose
500 micrograms/day · subcutaneous · 24 weeksAs given in this study (human).
Measurements
Uterine volume
296 cm3
four months after therapy
Source sentences
Summary
Four months after completing therapy, uterine volume increased to 296 +/- 104 cm3 in the SC group, which was not significantly different from pretreatment volume.
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen premenopausal women with uterine leiomyomata were randomized to receive a gonadotropin-releasing hormone agonist (GnRH-a), leuprolide, either by daily subcutaneous (SC) injection (500 micrograms/day) or by intranasal (IN) spray (1600 micrograms/day) for 24 weeks.
Report a problemFND-0311583306
06HumanObservational studyMechanism
In women treated with leuprolide, estradiol correlated negatively with percentage uterine volume decrease, r = -0.55, P less than 0.05.
In plain wordsIn women treated with leuprolide, higher estradiol was linked to a smaller percentage decrease in uterine volume.
Peptide
Leuprolide
Outcome
DecreaseEstradiol-volume correlation
Study
n = 14
Outcome group
Uterine Volume · Reproductive and sexual health
Studied dose
500 micrograms/day subcutaneously or 1600 micrograms/day intranasally · subcutaneous or intranasal · 24 weeksAs given in this study (human).
Measurements
Correlation coefficient
−0.55 r
estradiol versus percent uterine volume decrease
Source sentences
Summary
In addition, there was a significant negative correlation between the serum estradiol concentration during treatment and the percent decrease in uterine volume (r = -0.55, P less than 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
Fourteen premenopausal women with uterine leiomyomata were randomized to receive a gonadotropin-releasing hormone agonist (GnRH-a), leuprolide, either by daily subcutaneous (SC) injection (500 micrograms/day) or by intranasal (IN) spray (1600 micrograms/day) for 24 weeks.
Report a problemFND-0311583304

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.